391 related articles for article (PubMed ID: 28433570)
1. Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.
Soo RA; Kubo A; Ando M; Kawaguchi T; Ahn MJ; Ou SI
Clin Lung Cancer; 2017 Sep; 18(5):535-542. PubMed ID: 28433570
[TBL] [Abstract][Full Text] [Related]
2. Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer.
Kawaguchi T; Ando M; Kubo A; Takada M; Atagi S; Okishio K; Asami K; Matsumura A; Tsujino K; Ignatius OS; Sasaki H
Clin Cancer Res; 2011 Jan; 17(1):39-45. PubMed ID: 21059816
[TBL] [Abstract][Full Text] [Related]
3. Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study.
Torres-Durán M; Ruano-Ravina A; Kelsey KT; Parente-Lamelas I; Leiro-Fernández V; Abdulkader I; Provencio M; Abal-Arca J; Castro-Añón O; Montero-Martínez C; Vidal-García I; Amenedo M; Golpe-Gómez A; Martínez C; Guzmán-Taveras R; Mejuto-Martí MJ; Fernández-Villar A; Barros-Dios JM
Cancer Lett; 2017 Dec; 411():130-135. PubMed ID: 28987389
[TBL] [Abstract][Full Text] [Related]
4. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer.
Lee YJ; Cho BC; Jee SH; Moon JW; Kim SK; Chang J; Chung KY; Park IK; Choi SH; Kim JH
J Clin Oncol; 2010 Jan; 28(3):487-92. PubMed ID: 20008630
[TBL] [Abstract][Full Text] [Related]
5. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
Chapman AM; Sun KY; Ruestow P; Cowan DM; Madl AK
Lung Cancer; 2016 Dec; 102():122-134. PubMed ID: 27987580
[TBL] [Abstract][Full Text] [Related]
7. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Lee SH; Kim SJ; Yoon HK; Kim TJ; Lee KY
PLoS One; 2015; 10(11):e0142306. PubMed ID: 26555338
[TBL] [Abstract][Full Text] [Related]
8. No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
Couraud S; Debieuvre D; Moreau L; Dumont P; Margery J; Quoix E; Duvert B; Cellerin L; Baize N; Taviot B; Coudurier M; Cadranel J; Missy P; Morin F; Mornex JF; Zalcman G; Souquet PJ;
Eur Respir J; 2015 May; 45(5):1415-25. PubMed ID: 25745045
[TBL] [Abstract][Full Text] [Related]
9. A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population.
Hong S; Fang W; Hu Z; Zhou T; Yan Y; Qin T; Tang Y; Ma Y; Zhao Y; Xue C; Huang Y; Zhao H; Zhang L
Sci Rep; 2014 Dec; 4():7268. PubMed ID: 25434695
[TBL] [Abstract][Full Text] [Related]
10. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
11. Proportion and clinical features of never-smokers with non-small cell lung cancer.
Cho J; Choi SM; Lee J; Lee CH; Lee SM; Kim DW; Yim JJ; Kim YT; Yoo CG; Kim YW; Han SK; Park YS
Chin J Cancer; 2017 Feb; 36(1):20. PubMed ID: 28179026
[TBL] [Abstract][Full Text] [Related]
12. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
14. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
16. Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases.
Ruano-Ravina A; Torres-Durán M; Kelsey KT; Parente-Lamelas I; Leiro-Fernández V; Abdulkader I; Abal-Arca J; Montero-Martínez C; Vidal-García I; Amenedo M; Castro-Añón O; Golpe-Gómez A; González-Barcala J; Martínez C; Guzmán-Taveras R; Provencio M; Mejuto-Martí MJ; Fernández-Villar A; Barros-Dios JM
Eur Respir J; 2016 Nov; 48(5):1462-1470. PubMed ID: 27799390
[TBL] [Abstract][Full Text] [Related]
17. [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].
Wang X; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Sep; 21(9):686-691. PubMed ID: 30201068
[TBL] [Abstract][Full Text] [Related]
18. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH
Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
20. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G;
Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
